ArticleWorld journal of surgical oncology2026
Development of a prognostic model for thyroid cancer based on mitochondrial metabolism-related genes and immune profiling.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Computational prioritization of candidate TCDD-associated targets in retinoblastoma using network toxicology and transcriptomic analysis.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe preliminary study found that mitochondrial metabolism and structure are abnormal in thyroid cancer (THCA) patients. Therefore, this study systematically investigates the relationship between mitochondrial metabolism-related genes (MMRGs) and the prognosis of THCA patients, while establishing a prognostic model for THCA.
methodsThis study utilized THCA transcriptome data from the UCSC Xena database, performed differential expression analysis using the “limma” package, and intersected differentially expressed genes (DEGs) with MMRG to identify differentially expressed MMRGs (DEMMRGs). THCA prognostic genes were identified using the least absolute shrinkage and selection operator (LASSO) regression and multivariate Cox regression analysis, and a prognostic model was constructed. Using ssGSEA, CIBERSORT and Immune Phenotype Score methods, we compared differences in immune cell infiltration levels and anti-tumor immune response capacity between distinct risk groups. Furthermore, molecular subtypes of THCA were identified through consensus clustering analysis.
resultsThis study systematically identified nine MMRGs to construct a robust prognostic prediction model for THCA. Enrichment analysis revealed that patients in the low-risk group exhibited significant enrichment in multiple immune-related pathways, such as T cell-mediated immune responses to tumor cells, and demonstrated stronger responsiveness to anti-CTLA-4 and anti-PD-1 immunotherapies compared to the high-risk group. Further analysis identified two distinct molecular subtypes of THCA: Group 2 exhibited upregulation of immune checkpoint molecules, elevated ESTIMATEScore and StromalScore, and lower TumorPurity.
conclusionThis study adopts the unique perspective of MMRGs to elucidate their pivotal role and molecular basis within the THCA tumor microenvironment, offering novel insights for deepening our understanding of the disease’s pathogenesis and developing innovative therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.